Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Kobayashi T, Kubo E, Takahashi Y, et al. Retinal vessel changes in galactose-fed dogs. Arch Ophthalmol 1998;116:785–789.
-
2. de Schaepdrijver L, Simoens P, Lauwers H. Fluorescein angiography of the canine retina. Vet Comp Ophthalmol 1996;6:111–119.
-
3. Narfström K, Vaegan, Katz M, et al. Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 2005;111:39–48.
-
4. Pizzirani S, Davidson MG, Gilger BC. Transpupillary diode laser retinopexy in dogs: ophthalmoscopic, fluorescein angiographic and histopathologic study. Vet Ophthalmol 2003;6:227–235.
-
5. Grahn BH, Sandmeyer LL, Breaux C. Retinopathy of coton detulear dogs: clinical manifestations, electroretinographic, ultrasonographic, fluorescein and indocyanine green angiographic, and optical coherence tomographic findings. Vet Ophthalmol 2008;11:242–249.
-
6. Pitet G, Amalric P, Hygounenc O. Etude anlytique de la fluorescence des solutions de fluoresceinate de sodium. In: Amalric P, ed. Fluorescein angiography: proceedings of the international symposium on fluorescein angiography Albi (France) 1969. Basel, Switzerland: S. Karger, 1971;8–11.
-
7. Novotny HR, Alvis DL. A method of photographing fluorescence in circulating blood in the human retina. Circulation 1961;24:82–86.
-
8. Chahal PS, Neal MJ, Kohner EM. Metabolism of fluorescein after intravenous administration. Invest Ophthalmol Vis Sci 1985;26:764–768.
-
9. Pinhas A, Dubow M, Shah N, et al. In vivo imaging of human retinal microvasculature using adaptive optics scanning light ophthalmoscope fluorescein angiography. Biomed Opt Express 2013;4:1305–1317.
-
10. Leila L. Adverse effects of fluorescein angiography. Acta Ophthalmol Scand 2006;84:720–721.
-
11. Lira RPC, Oliveira CL, Marques MV, et al. Adverse reactions of fluorescein angiography: a prospective study. Arq Bras Oftalmol 2007;70:615–618.
-
12. Butner RW, McPherson AR. Adverse reactions in intravenous fluorescein sodium angiography. Ann Ophthalmol 1983;15:1084–1086.
-
13. Yannuzzi LA, Justice J Jr, Baldwin HA. Effective differences in the formulation of intravenous fluorescein sodium and related side effects. Am J Ophthalmol 1974;78:217–221.
-
14. Stein MR, Parker CW. Reactions following intravenous fluorescein sodium. Am J Ophthalmol 1971;72:861–868.
-
15. Acheson R, Serjeant G. Painful crises in sickle cell disease after fluorescein sodium angiography. Lancet 1985;1:1222.
-
16. Balbino M, Silva G, Correia GC. Anaphylaxis with convulsions following intravenous fluorescein sodium angiography at an outpatient clinic. Einstein (Sao Paulo) 2012;10:374–376.
-
17. Ha SO, Kim DY, Sohn CH, et al. Anaphylaxis caused by intravenous fluorescein sodium: clinical characteristics and review of literature. Intern Emerg Med 2014;9:325–330.
-
18. Bearelly S, Rao S, Fekrat S. Anaphylaxis following intravenous fluorescein sodium angiography in a vitreoretinal clinic: report of 4 cases. Can J Ophthalmol 2009;44:444–445.
-
19. Kwiterovich KA, Maguire MG, Murphy RP, et al. Frequency of adverse systemic reactions after fluorescein sodium angiography. Results of a prospective study. Ophthalmology 1991;98:1139–1142.
-
20. Ascaso FJ, Tiestos MT, Navales J, et al. Fatal acute myocardial infarction after intravenous fluorescein angiography. Retina 1993;13:238–239.
-
21. Elman MJ, Fine SL, Sorenson J, et al. Skin necrosis following fluorescein extravasation. A survey of the Macula Society. Retina 1987;7:89–93.
-
22. Yannuzzi LA, Rohrer KT, Tindel LJ, et al. Fluorescein angiography complication survey. Ophthalmology 1986;93:611–617.
-
23. Gómez-Ulla F, Gutiérrez C, Seoane I. Severe anaphylactic reaction to orally administered fluorescein. Am J Ophthalmol 1991;112:94.
-
24. Kinsella FP. Mooney DJ. Anaphylaxis following oral fluorescein angiography. Am J Ophthalmol 1988;106:745–746.
-
25. Gelatt KN, Henderson JD, Steffen GR. Fluorescein angiography of the normal and diseased ocular fundi of the laboratory dog. J Am Vet Med Assoc 1976;169:980–984.
-
26. Davidson MG, Baty KT. Anaphylaxis associated with intravenous sodium fluorescein administration in a cat. Prog Vet Comp Ophthal 1991;1:127–128.
-
27. Rajagopalan R, Neumann WL, Poreddy AR, et al. Hydrophilic pyrazine dyes as exogenous fluorescent tracer agents for real-time point-of-care measurement of glomerular filtration rate. J Med Chem 2011;54:5048.
-
28. Dorshow RB, Debreczeny MP, Fink JC, et al. Initial clinical trial results of a real-time point-of-care glomerular filtration rate measurement utilizing a novel fluorescent tracer agent. J Am Soc Nephrol 2015;26:259A.
-
29. Dorshow RB, Debreczeny M, Johnson JR, et al. Clinical study results of a real-time point-of-care glomerular filtration rate measurement. J Am Soc Nephrol 2017;28:597.
-
30. Bugaj JE, Dorshow RB. Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate. Regul Toxicol Pharmacol 2015;72:26–38.
-
31. Dorshow RB, Bugaj JE. Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate. Regul Toxicol Pharmacol 2019;107:104417.
-
32. Alario AF, Pirie CG, Pizzirani S. Anterior segment fluorescein angiography of the normal canine eye using a DSLR camera adapter. Vet Ophthalmol 2013;16:10–19.
-
33. Rockey JH, Li W, Eccleston JF. Binding of fluorescein and carboxyfluorescein by human serum proteins: significance of kinetic and equilibrium parameters of association in ocular fluorometric studies. Exp Eye Res 1983;37:455–466.
-
34. Li W, Rockey JH. Fluorescein binding to normal human serum proteins demonstrated by equilibrium dialysis. Arch Ophthalmol 1982;100:484–487.
-
35. Kottow M. Anterior segment fluorescein angiography. Baltimore: Williams & Wilkins, 1978;35–55.
-
36. Brancato R, Bandello F, Lattanzio R. Iris fluorescein angiography in clinical practice. Surv Ophthalmol 1997;42:41–70.
Advertisement
Effectiveness of MB-102, a novel fluorescent tracer agent, for conducting ocular angiography in dogs
Abstract
OBJECTIVE
To evaluate the effectiveness of a novel fluorescence tracer agent, MB-102, for conducting ocular angiography in dogs.
ANIMALS
10 ophthalmologically normal dogs (2 to 4 years old) and 10 dogs with retinal degeneration or primary open-angle glaucoma (< 6 years old).
PROCEDURES
While anesthetized, all dogs received sodium fluorescein (20 mg/kg, IV) or MB-102 (20 or 40 mg/kg, IV) first and then the other dye in a second treatment session 2 days later in a randomized crossover design. Anterior fluorescence angiography was performed on one eye and posterior fluorescence angiography on the other. Imaging was performed with a full-spectrum camera and camera adaptor system. Filter sets that were tailored to match the excitation and emission characteristics of each angiographic fluorescent agent were used.
RESULTS
All phases and phase intervals during anterior and posterior segment angiography were identified, regardless of the dye used. However, agent fluorescence and visualization of the iridal blood vessels were hindered in some dogs, irrespective of agent, owing to the degree of iridal pigmentation present. No significant difference was noted between the 2 dyes in any phase or phase interval, and slight improvement in image contrast was observed with MB-102 during the venous phases owing to a reduction of vessel wall staining in both normal and diseased eyes.
CONCLUSIONS AND CLINICAL RELEVANCE
Results suggested that MB-102 would be useful for conducting ocular angiography in dogs.
Supplementary Materials
- Supplementary Appendix 1 (PDF 994 kb)
Contributor Notes
Dr. Pirie's present address is the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824.
Powered by PubFactory